This month brought several developments that shaped India's pharma industry, from new partnerships and licensing agreements to R&D expansion and international market opportunities
Zydus Lifesciences just moved the needle in the global fight against liver disease. The company's EVIDENCES-X Phase II trial for Saroglitazar Mg met its primary endpoint, with 26.5 percent treatment difference over placebo to resolve steatohepatitis
Aurobindo Pharma has marked a major milestone as its US subsidiary, Lannett Company LLC, launched the generic version of Advair Diskus in the American market on 31 August 2026
India-Brazil Trade is set for a major expansion as both countries target USD 30 billion in bilateral trade by 2030. The India-Brazil Trade partnership is also gaining momentum through wider market access for Indian pharmaceutical products.
India’s H1N1 cases continue to draw attention as more states strengthen surveillance and hospital preparedness. Jharkhand is now the latest state to step up its response after eight people tested positive for H1N1.
Regulatory actions from the USFDA and Maharashtra FDA dominated pharma news today. Companies secured key product approvals while others faced inspection findings and enforcement steps
The WHO science council has been renewed with 21 scientists and experts to help guide the future of global health. The World Health Organization announced the new membership.
The biggest pharma stories this week covered drug approvals, vaccines, medical devices, wellness investments, and emerging health research. These pharma stories also showed how quickly healthcare priorities are changing across India and global...
India is seeing an H1N1 flu surge, and flu vaccine demand has jumped sharply as influenza cases rise across the country. Vaccine sales are now nearly three times higher than last year. The demand has also more than doubled compared with July.
Drug development could see a major shift as Huawei expands its artificial intelligence partnerships with pharmaceutical companies
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")